The study results indicate that, from the perspective of the Chinese healthcare system, CAD-CHM as a first-line treatment for HER2-negative advanced G/GEJ adenocarcinoma lacks cost-effectiveness compared with chemotherapy alone, irrespective of PD-L1 CPS subgroup stratification. This evidence concerns the gene ERBB2 and gastroesophageal junction adenocarcinoma.